Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regeneron's VEGF Trap-Eye Caught In CATT's Claws

This article was originally published in The Pink Sheet Daily

Executive Summary

Regeneron's VEGF Trap-Eye is caught in the crosshairs in the comparative efficacy debate over Avastin and Lucentis.

You may also be interested in...



Allergan Licenses Molecular Partners' Anti-VEGF Protein For Ophthalmologic Indications

Privately held Swiss firm gets $45 million upfront in deal for Phase II candidate being studied in wet age-related macular degeneration and diabetic macular edema.

Allergan Licenses Molecular Partners' Anti-VEGF Protein For Ophthalmologic Indications

Privately held Swiss firm gets $45 million upfront in deal for Phase II candidate being studied in wet age-related macular degeneration and diabetic macular edema.

Lucentis And Avastin Stack Up In CATT, Forcing Genentech/Novartis To Play Defense

The efficacy of low-cost Avastin and pricier Lucentis for the treatment of wet-AMD are similar in the first head-to-head clinical trial to compare the two drugs, though Novartis and Genentech call out safety uncertainties.

Topics

UsernamePublicRestriction

Register

PS072323

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel